115 related articles for article (PubMed ID: 8560408)
1. Elimination of acquired factor VIII antibodies by extracorporal antibody-based immunoadsorption (Ig-Therasorb).
Knöbl P; Derfler K; Korninger L; Kapiotis S; Jäger U; Maier-Dobersberger T; Hörl W; Lechner K; Pabinger I
Thromb Haemost; 1995 Oct; 74(4):1035-8. PubMed ID: 8560408
[TBL] [Abstract][Full Text] [Related]
2. Removal of baboon and human antiporcine IgG and IgM natural antibodies by immunoadsorption. Results of in vitro and in vivo studies.
Leventhal JR; John R; Fryer JP; Witson JC; Derlich JM; Remiszewski J; Dalmasso AP; Matas AJ; Bolman RM
Transplantation; 1995 Jan; 59(2):294-300. PubMed ID: 7839454
[TBL] [Abstract][Full Text] [Related]
3. Treatment of coagulation inhibitors with extracorporeal immunoadsorption (Ig-Therasorb).
Jansen M; Schmaldienst S; Banyai S; Quehenberger P; Pabinger I; Derfler K; Hörl WH; Knöbl P
Br J Haematol; 2001 Jan; 112(1):91-7. PubMed ID: 11167789
[TBL] [Abstract][Full Text] [Related]
4. Extracorporeal immunoadsorption for the treatment of haemophilic patients with inhibitors to factor VIII or IX.
Knöbl P; Derfler K
Vox Sang; 1999; 77 Suppl 1():57-64. PubMed ID: 10529691
[TBL] [Abstract][Full Text] [Related]
5. Reduction of acquired high titer factor VIII antibodies by extracorporeal antibody-based immunoadsorption without additional immunosuppressive therapy.
Toepfer M; Rommel F; Sitter T; Spannagl M; Held E; Schramm W; Schiffl H
Thromb Haemost; 1998 Dec; 80(6):1035-6. PubMed ID: 9869185
[No Abstract] [Full Text] [Related]
6. Rapid elimination of a high-titer spontaneous factor V antibody by extracorporeal antibody-based immunoadsorption and immunosuppression.
Tribl B; Knöbl P; Derfler K; Kapiotis S; Aspöck G; Jäger U; Hörl W; Lechner K
Ann Hematol; 1995 Oct; 71(4):199-203. PubMed ID: 7578528
[TBL] [Abstract][Full Text] [Related]
7. [Comparison of anti-human and anti-porcine factor VIII antibody titers in patients with hemophilia].
Windyga J; Rzymkiewicz L; Lopaciuk S
Acta Haematol Pol; 1996; 27(1):27-31. PubMed ID: 8629440
[TBL] [Abstract][Full Text] [Related]
8. Apheresis.
Nilsson IM; Freiburghaus C
Adv Exp Med Biol; 1995; 386():175-84. PubMed ID: 8851026
[TBL] [Abstract][Full Text] [Related]
9. Extracorporeal immunoadsorption for the treatment of coagulation inhibitors.
Franchini M; Sassi M; Dell'Anna P; Manzato F; Salvagno GL; Montagnana M; Zaffanello M; Targher G; Lippi G
Semin Thromb Hemost; 2009 Feb; 35(1):76-80. PubMed ID: 19308895
[TBL] [Abstract][Full Text] [Related]
10. The course of anticardiolipin antibody levels under immunoadsorption therapy.
Hauser AC; Hauser L; Pabinger-Fasching I; Quehenberger P; Derfler K; Hörl WH
Am J Kidney Dis; 2005 Sep; 46(3):446-54. PubMed ID: 16129206
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of CD40 ligand (CD154) in the treatment of factor VIII inhibitors.
Ewenstein BM; Hoots WK; Lusher JM; DiMichele D; White GC; Adelman B; Nadeau K
Haematologica; 2000 Oct; 85(10 Suppl):35-9. PubMed ID: 11187868
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of different immunoadsorption columns for anti-A/B antibody depletion.
Speer C; Kälble F; Pego da Silva L; Nusshag C; Schaier M; Becker LE; Klein K; Beimler J; Sommerer C; Leo A; Süsal C; Mehrabi A; Zeier M; Morath C
Atheroscler Suppl; 2019 Dec; 40():68-72. PubMed ID: 31447215
[TBL] [Abstract][Full Text] [Related]
13. [Immunoadsorption therapy for myasthenia gravis: study on the adsorption capacity of an immunoadsorption column].
Yeh JH; Chiu HC
J Microbiol Immunol Infect; 1999 Jun; 32(2):121-5. PubMed ID: 11565565
[TBL] [Abstract][Full Text] [Related]
14. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy.
Kubisz P; Plamenová I; Hollý P; Stasko J
Med Sci Monit; 2009 Jun; 15(6):CS105-11. PubMed ID: 19488019
[TBL] [Abstract][Full Text] [Related]
15. Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate.
Peerlinck K; Arnout J; Di Giambattista M; Gilles JG; Laub R; Jacquemin M; Saint-Remy JM; Vermylen J
Thromb Haemost; 1997 Jan; 77(1):80-6. PubMed ID: 9031454
[TBL] [Abstract][Full Text] [Related]
16. [Immunoadsorption therapy for Fisher's syndrome: analysis of the recovery process of external ophthalmoplegia and the removal ability of anti-GQ1b antibodies].
Chida K; Watanabe S; Okita N; Takase S; Tagawa Y; Yuki N
Rinsho Shinkeigaku; 1996 Apr; 36(4):551-6. PubMed ID: 8810848
[TBL] [Abstract][Full Text] [Related]
17. Factor VIII antibodies in rheumatoid arthritis. Effect of cyclophosphamide.
Green D; Schuette PT; Wallace WH
Arch Intern Med; 1980 Sep; 140(9):1232-5. PubMed ID: 6773487
[TBL] [Abstract][Full Text] [Related]
18. Rituximab for the treatment of patients with very high-titre acquired factor VIII inhibitors refractory to conventional chemotherapy.
Field JJ; Fenske TS; Blinder MA
Haemophilia; 2007 Jan; 13(1):46-50. PubMed ID: 17212724
[TBL] [Abstract][Full Text] [Related]
19. ABO-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab: a single center experience.
Donauer J; Wilpert J; Geyer M; Schwertfeger E; Kirste G; Drognitz O; Walz G; Pisarski P
Xenotransplantation; 2006 Mar; 13(2):108-10. PubMed ID: 16623802
[TBL] [Abstract][Full Text] [Related]
20. [Immunosuppressive treatment of a spontaneous inhibitor hemophilia A using cyclophosphamide, vincristine and prednisone following prior Factor VIII stimulation].
Dürig J; de Wit M; Fiedler W; Marx G; Hossfeld DK
Schweiz Med Wochenschr; 1996 Nov; 126(47):2026-31. PubMed ID: 8984611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
